Corvus Pharmaceuticals (CRVS) Free Cash Flow (2015 - 2026)

Corvus Pharmaceuticals' Free Cash Flow history runs 12 years deep, the most recent figure standing at -$10.5 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 26.1% year-over-year to -$10.5 million in Q1 2026; TTM through Mar 2026 was -$34.6 million, a 19.9% decrease from a year earlier, with the FY2025 full-year figure at -$32.5 million, down 27.53% from the prior year.
• Free Cash Flow eased to -$10.5 million in Q1 2026 per CRVS's latest filing, from -$8.7 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$4.9 million in Q1 2024 and bottomed at -$10.5 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$6.4 million (2022), against an average of -$7.0 million.
• Across the five-year window, Free Cash Flow surged 48.48% in 2022 and plunged 81.11% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at -$7.8 million in 2022, then soared by 33.79% to -$5.2 million in 2023, then plunged by 81.11% to -$9.4 million in 2024, then grew by 6.99% to -$8.7 million in 2025, then dropped by 20.23% to -$10.5 million in 2026.
• Per Business Quant, the three latest CRVS Free Cash Flow figures stand at -$10.5 million (Q1 2026), -$8.7 million (Q4 2025), and -$9.9 million (Q3 2025).